Skip to main content
Equibles
TTRX logo

TTRX · Turn Therapeutics Inc. · Metrics

Track TTRX — free

Use TTRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TTRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.48 +0.54 (+6.04%) At close · Nov 6
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our capital resources may not be sufficient to fund operations through at least the next 12 months from the date that the accompanying unaudited condensed consolidated interim financial statements as of June 30, 2026 are issued based on our expected cash needs, which raises substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$282.39M
Shares
29.79M
Volume · Nov 6 98.14K Avg daily vol (3M) 110.55K

TTRX metrics

62 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.48
Market cap
$282.39M

Price action

23 metrics
Price change (1W)
-16.6%
Price change (30D)
-26.1%
Price change (3M)
-7.0%
Price change (6M)
+135.6%
Price change (YTD)
+126.9%
Price change (1Y)
+106.9%
Trailing year
Price change (5Y)
—
52-week high
$15.34
52-week low
$2.71
Change from 52-week high
-41.7%
Change from 52-week low
+229.9%
Annualized volatility
100.0%
Annualized volatility (3M)
95.6%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.4
RSI (14D)
35.2
Price vs SMA 50
-23.7%
Price vs SMA 200
+26.0%
Avg volume (3M)
110,591
Relative volume
1.2
Average dollar volume
$1.35M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
29.79M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
387.7
reciprocal yield 0.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$6.98M
Net income (TTM)
−$8.45M
Trailing 12 months
Diluted EPS (TTM)
$-0.29
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.24
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.29
Operating cash flow per diluted share (TTM)
$-0.15
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.03
Stock compensation per diluted share (TTM)
$0.03
Book value per share
$0.16

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+8.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-1,229.6%
Return on assets
-49.8%
Debt / equity
10.6
Current ratio
1.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$2.69M
Latest balance sheet
Cash & equivalents
$9.95M
Total assets
$16.96M
Total debt
$7.26M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$4.32M
Capital expenditures (TTM)
—
R&D (TTM)
$778,131
SG&A (TTM)
—
Stock compensation (TTM)
$995,527
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
29
13F filer change QoQ
+9
Institutional ownership
3.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
1.2%
Private-fund adviser ownership
1.2%
Active holders' share change QoQ
+164.6%
Holder tenure
1.8
Price vs estimated holder cost
+63.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.4%

Short interest

3 metrics
Short interest
1.4%
Latest settlement · 4.3 days to cover
Days to cover
4.3d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 2023016 CUSIP 90021W105 13F (30d) 16 filings 16 filers Visit website Investor relations